Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ABIONYX Pharma S.A. (ABNX.PA)
Balma, FR
ABIONYX Pharma SA is a biotechnology company dedicated to the identification and advancement of therapies for conditions affecting the kidneys and eyes. The firm's pipeline includes CER-001, an innovative negatively-charged lipoprotein particle. This compound is designed to mimic the structural and functional attributes of pre-beta HDL, utilizing human recombinant apoA-I (a natural high-density lipoprotein protein) along with natural phospholipids like sphingomyelin and dipalmitoylphosphatidylglycerol. CER-001 is currently under development for patients recovering from acute coronary syndrome and those with familial primary hypoalphalipoproteinemia. Another key candidate, CER-002, is a specific agonist for peroxisome proliferator-activated receptor delta, targeting cardiovascular and metabolic diseases. Additionally, CER-209 is being developed as a potential treatment for metabolic liver diseases, atherosclerosis, and non-alcoholic steatohepatitis (NASH). ABIONYX maintains strategic partnerships with GTP Biologics and VBI Therapeutics Group for the bioproduction of its bio-HDL in France. Established in 2005, the company operated as Cerenis Therapeutics Holding SA before its rebranding to ABIONYX Pharma SA in August 2019. Its operations are headquartered in Balma, France.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.89% | -15.13% | -17.10% | -15.88% | -30.24% | -24.54% | +120.00% | +119.66% | +95.09% | -67.28% | -76.80% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-11.7% Q4'25: -22.6% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-23.1% Q4'25: -117.2% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-95.2% Q4'25: -67.7% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-154.0% Q4'25: -201.4% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-137.6% Q4'25: -313.6% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+5.4% Q4'25: +15.9% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.67× Q4'25: -0.28× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
675.0K
est: 670.0K (+0.7%)
|
5.25M
est: 5.25M (+0.0%)
|
4.64M
est: 4.86M (-4.4%)
|
4.60M
est: 4.60M (+0.0%)
|
4.06M
est: 4.56M (-10.9%)
|
4.66M
4.10M – 5.22M
+2.2% YoY
|
14.77M
4.10M – 25.43M
+216.9% YoY
|
37.66M
37.66M – 37.66M
+155.0% YoY
|
| EBITDA |
-7.42M
est: -370.3K (-1,903.2%)
|
-4.01M
est: -2.90M (-38.2%)
|
-4.84M
est: -4.63M (-4.7%)
|
-4.93M
est: -4.38M (-12.4%)
|
-5.70M
est: -4.34M (-31.3%)
|
-4.44M
-4.97M – -3.91M
-2.2% YoY
|
-14.07M
-24.23M – -3.91M
-216.9% YoY
|
-35.88M
-35.88M – -35.88M
-155.0% YoY
|
| EBIT |
-7.54M
est: -373.8K (-1,916.6%)
|
-4.15M
est: -2.93M (-41.5%)
|
-4.68M
est: -4.65M (-0.7%)
|
-5.41M
est: -4.41M (-22.7%)
|
-6.26M
est: -4.37M (-43.2%)
|
-4.46M
-5.00M – -3.93M
-2.2% YoY
|
-14.14M
-24.36M – -3.93M
-216.9% YoY
|
-36.07M
-36.07M – -36.07M
-155.0% YoY
|
| Net Income |
-5.82M
est: -4.65M (-25.1%)
|
-4.21M
est: -7.46M (+43.6%)
|
-3.52M
est: -3.36M (-4.8%)
|
-4.40M
est: -4.60M (+4.3%)
|
-5.55M
est: -5.50M (-0.9%)
|
-16.51M
-18.47M – -14.56M
-200.2% YoY
|
-10.52M
-11.09M – -9.94M
+36.3% YoY
|
-39.97M
-52.65M – -7.48M
-280.0% YoY
|
| SGA |
503.0K
est: 333.6K (+50.8%)
|
1.19M
est: 2.61M (-54.5%)
|
1.11M
est: 2.55M (-56.6%)
|
1.29M
est: 2.41M (-46.7%)
|
4.60M
est: 2.39M (+92.4%)
|
2.44M
2.15M – 2.74M
+2.2% YoY
|
7.74M
2.15M – 13.34M
+216.9% YoY
|
19.74M
19.74M – 19.74M
+155.0% YoY
|
| EPS |
-0.23
est: -0.14 (-66.5%)
|
-0.15
est: -0.22 (+32.3%)
|
-0.12
est: -0.11 (-12.1%)
|
-0.13
est: -0.16 (+18.8%)
|
-0.16
est: -0.23 (+31.8%)
|
-0.47
-0.52 – -0.41
-98.3% YoY
|
-0.30
-0.31 – -0.28
+36.3% YoY
|
-0.85
-1.48 – -0.21
-185.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sir Cyrille Tupin | Chief Executive Officer, GM & Director | 310.8K | — |
| Christian Chavy | Independent Director | 30.3K | — |
| Constance Keyserling | Vice President of Clinical, Regulatory Development & Operations | — | female |
| Emmanuel De Fougeroux | Administrative & Financial Director | — | male |
| Laurent Guerci | Chief Digital & Innovation Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ABNX.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
